PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Ixekizumab - Psoriasis

PAD Profile : Ixekizumab - Psoriasis

Keywords :
Biologic, interleukin 17A (IL-17A) inhibitor, Dermatology, plaque psoriasis, monoclonal antibody, cytokine modulator, immunosuppression, systemic therapy, NICE
Brand Names Include :
Taltz

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
ICB
BlueTeq
NICE
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Guidelines (Local)
Psoriasis - High cost immunomodulator treatment pathway - October 23.pdf
31 October 2026
NICE Technology Appraisal
NICE TA442 - Ixekizumab for moderate to severe plaque psoriasis
Evidence Review
Ixekizumab for psoriasis - Briefing paper - July 2017

Committee Recommendations

Date
Committee Name
Narrative
04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.

02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriasis High Cost immunomodulator Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. The agreed process and associated documentation is saved here https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6549

05 July 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Ixekizumab as a treatment option for treating moderate to severe plaque psoriasis in line with NICE and associated treatment pathways. Prescribing will be by hospital specialists only, in line with NICE TA442 using Blueteq initiation and continuation forms. Ixekizumab will be considered RED on the traffic light system.

Associated BNF Codes

13. Skin
13.05.02. Preparations for psoriasis
13.05.03. Drugs affecting the immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More